Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

AffaMed Closes $170 Million Financing for In-licensed Portfolio

publication date: Mar 30, 2021

AffaMed Therapeutics, a Shanghai biopharma, closed a $170 million Series B financing to develop treatments for ophthalmic, neurological and psychiatric disorders. Formed in 2019 by CBC Group, AffaMed merged last fall with EverInsight, a Shanghai company with a similar focus. In 2019, AffaMed in-licensed its first three ophthalmology candidates from Korea's Bioepis. It will use the proceeds to advance clinical development of its pipeline, augment business development and prepare for commercialization. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital